|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 7,731,690
Summary
Patent 7,731,690, issued on June 8, 2010, and assigned to Amgen Inc., primarily covers a class of recombinant erythropoietin (EPO) molecules with specific glycosylation profiles, methods of manufacturing these molecules, and their therapeutic applications. This patent plays a significant role in erythropoiesis-stimulating agents’ (ESAs) patent landscape, particularly for drugs like epoetin alfa and darbepoetin alfa. It claims engineered EPO molecules with enhanced stability and efficacy, marking a substantial advance over prior art.
This report provides an in-depth review of the patent's scope and claims, contextualizes it within the broader patent landscape, details its influence on subsequent filings, and discusses strategic implications for stakeholders.
1. Overview of Patent 7,731,690
| Aspect |
Detail |
| Title |
"Glycoforms of erythropoietin with increased biological activity" |
| Filing Date |
March 31, 2004 |
| Issue Date |
June 8, 2010 |
| Assignee |
Amgen Inc. |
| Priority Date |
March 31, 2003 (provisional application) |
| Field |
Biopharmaceuticals, glycoengineering, recombinant protein therapeutics |
1.1. Main Focus
The patent claims include recombinant human erythropoietin (rHuEPO) with specific glycoform profiles, particularly increased sialylation, resulting in enhanced stability, longer serum half-life, and increased in vivo activity. The invention emphasizes glycosylation modifications to improve pharmacokinetics.
2. Scope and Key Claims
| Claim Type |
Major Claims & Features |
Details |
| Glycoform Composition |
Claims recombinant EPO molecules with specific carbohydrate structures |
Emphasizes increased sialic acid content (e.g., >9 moles of sialic acid per mole of EPO), compared to native EPO, to enhance in vivo activity. |
| Method of Production |
Claims methods to produce these glycoforms |
Utilizes glycoengineering techniques such as cell line modifications, fermentation conditions, and enzymatic treatment to modify glycosylation patterns. |
| Pharmacokinetic Properties |
Claims molecules with prolonged serum half-life |
Demonstrates increased half-life through enhanced sialylation, leading to less rapid clearance. |
| Efficacy & Stability |
Claims that the glycoforms exhibit increased stability and biological activity |
Validated through in vitro and in vivo assays, including increased erythropoietic activity in animal models. |
| Therapeutic Use |
Claims use of these glycoforms in treating anemia |
Applicable to chronic kidney disease (CKD), chemotherapy-induced anemia, and other indications. |
2.1. Representative Claims
| Claim Number |
Summary |
Technical Features |
| Claim 1 |
Recombinant EPO with ≥9 mols of sialic acid per mol of EPO |
Specifies glycoform composition; critical for extended half-life. |
| Claim 4 |
Method for producing EPO glycoforms with increased sialylation via cell line engineering |
Uses host cells modified to express glycosyltransferases or glycosidases. |
| Claim 10 |
Pharmaceutical composition comprising EPO with enhanced glycosylation |
Focused on formulation for therapeutic use with specified glycoforms. |
| Claim 15 |
Use of glycoengineered EPO for treating anemia |
Claims method of therapy using the glycoengineered EPO. |
3. Patent Landscape Context
3.1. Prior Art
| Patent / Publication |
Focus |
Notable Features |
Relevance to 7,731,690 |
| U.S. Patent 6,316,999 |
Recombinant EPO glycosylation |
Glycosylation affects half-life; general methods |
Foundations for glycoengineering in EPO; prior to 7,731,690. |
| WO 98/57675 |
Glycosylation modifications for increased stability |
Enzymatic treatment to modify glycosylation |
Similar strategies but less specific. |
| U.S. Patent 5,593,852 |
Use of erythropoietin in anemia |
Therapeutic application; no specific glycoform claims |
Established the therapeutic landscape. |
3.2. Patent Families and Related Applications
| Patent Family or Application |
Filing Date |
Key Claims |
Notes |
| WO 2004/076789 (Amgen) |
Dec 16, 2004 |
Glycoengineered EPO variants with increased sialylation |
Continuation or related patent. |
| US Application 2005/0228500 |
Mar 31, 2005 |
Glycoforms with controlled glycosylation |
Key for defining scope. |
3.3. Subsequent Patents Influenced
| Patent / Company |
Focus |
Relation to 7,731,690 |
| Roche’s Patents (e.g., US 8,273,764) |
Erythropoietin formulations |
Build upon glycoengineering concepts. |
| His-Wentian et al. |
Glycan modifications |
Scientific literature expanding on similar modifications. |
4. Strategic and Commercial Implications
| Aspect |
Analysis |
| Patent Strength |
Broad claims on glycoforms with specified sialic acid content provide robust protection. |
| Scope Limitations |
Claims focus on glycoforms with specific sialylation levels; alternative modifications may avoid infringement. |
| Lifecycle & Expiry |
Filed in 2004, expected expiry around 2022-2024, subject to patent term adjustments. |
| Infringement Risks |
Biosimilar manufacturers exploring alternative glycoengineering or different production methods to bypass claims. |
| Licensing Opportunities |
Opportunities for deal-making with Amgen or licensing agreements for biosimilars. |
5. Comparative Analysis with Similar Patents
| Feature |
U.S. Patent 7,731,690 |
Related Patents |
Differentiators |
| Glycoform Content |
≥9 mols of sialic acid per mol of EPO |
Typically 4–7 mols in native EPO |
Elevated sialylation for longer half-life. |
| Production Methods |
Glycoengineering via cell lines |
Enzymatic modification, fermentation |
Focused on host cell modifications for consistency. |
| Therapeutic Claims |
Treating anemia with specific glycoforms |
Broader or unrelated glycoforms |
Specificity for glycoform profile. |
6. Frequently Asked Questions (FAQs)
Q1: How does Patent 7,731,690 define the glycoform profile critical for its claims?
A: The patent emphasizes recombinant EPO molecules with at least 9 mols of sialic acid per mol of EPO, which correlates with enhanced stability and in vivo activity. It specifies glycoforms with increased sialylation achieved through genetic or enzymatic methods.
Q2: What are the primary methods taught to produce the glycoforms claimed?
A: Amgen discloses genetic modifications of host cell lines (e.g., CHO cells) to overexpress glycosyltransferases, enzymatic treatments, and optimized fermentation conditions to increase sialylation levels in recombinant EPO.
Q3: How broad are the claims, and what do they exclude?
A: The claims are specific to EPO glycoforms with defined sialic acid content, particularly ≥9 mols per mol of EPO. They exclude glycoforms with lower sialylation levels and potentially other modifications not explicitly claimed.
Q4: What is the patent’s current legal status and expiration?
A: As of 2023, the patent is expected to expire in 2022-2024 due to patent term adjustments, pending legal status, and jurisdictional considerations. It remains enforceable in the U.S. until expiration.
Q5: What implications does this patent landscape have for biosimilar developers?
A: Developers must design glycoengineered EPO or alternative formulations that avoid infringement, such as differing glycan profiles or manufacturing methods, or seek licensing from Amgen.
7. Key Takeaways
- Patent claims focus on highly sialylated recombinant EPO glycoforms, which confer pharmacokinetic advantages by extending serum half-life.
- Production strategies involve sophisticated glycoengineering via cell line modification, enzymatic treatments, and fermentation optimization.
- The patent landscape features overlapping technologies, with prior art establishing glycosylation as a key factor, but 7,731,690 claims a specific glycoform profile with demonstrable therapeutic benefits.
- Legal scope is narrow but strategically significant, especially as the patent approaches expiration.
- For biosimilar entrants, designing around these claims requires alternative glycoform profiles or different modification techniques.
References
[1] U.S. Patent 7,731,690. “Glycoforms of erythropoietin with increased biological activity.” Issued June 8, 2010.
[2] U.S. Patent 6,316,999. “Methods for producing glycosylated erythropoietin.” 2001.
[3] WO 98/57675. “Glycosylation of erythropoietin.” 1998.
[4] U.S. Patent 5,593,852. “Erythropoietin for treatment of anemia.” 1997.
[5] Amgen Inc., “Erythropoietin glycoforms and methods,” various publications, 2000–2005.
End of Report
More… ↓
⤷ Start Trial
|
